Development of a New Longitudinal Ordinal Outcome for Clinical Trials in Extracorporeal Membrane Oxygenation Patients
Authors' conclusion
The DOSE outcome performed well compared with a patient-centered outcome. Compared with 28-day mortality, DOSE provided more statistical power in a simulated two-arm clinical trial.
Study context
- Population
- Adults admitted to ICU who received any type of ECMO, 28 hospitals in Australia and New Zealand, February 2019–September 2023
- Participants
- 1,375 adults · 28 hospitals
- Exposure
- DOSE outcome vs 28-day mortality alone
- Outcome
- Prediction of death and new disability by DOSE; simulated power vs 28-day mortality
- Follow-up
- 6 months
Methodological detailsmulticentre, simulation study
- Multicentre
- Simulation study
Main finding
As reported in the abstract
DOSE predicted death and new disability at 6 months, AUC
> 0.800
Power, 28-day mortality vs DOSE (400 per arm, OR 1.20)
36% vs. 91%
Additional power with DOSE vs 28-day mortality
56%
Observational data: associations, not effects.
Further findings
Death by ECMO type · Day 90
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Development of a New Longitudinal Ordinal Outcome for Clinical Trials in Extracorporeal Membrane Oxygenation Patients. Am J Respir Crit Care Med. Published 1 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →